Information Provided By:
Fly News Breaks for June 19, 2015
TKMR
Jun 19, 2015 | 14:33 EDT
Leerink says that while the TKM-Ebola-Guinea field trial update is "clearly disappointing " for Tekmira's Ebola program, the main long-term driver for shares is still the company's hepatitis B program. The firm does not see any significant read-through to Tekmira's other programs and reiterates an Outperform rating on the stock. Leerink notes its $30 price target attributes only $1 to TKM-Ebola.
News For TKMR From the Last 2 Days
There are no results for your query TKMR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.